Metabolic dysfunction-associated liver disease is a significant healthcare concern and burden. Until recently there was no approved pharmacologic treatment for the more serious form of the disease, metabolic dysfunction-associated steatohepatitis.
In this wide-ranging conversation, Prof. Vlad Ratziu explains the rationale behind the recently updated subclassification and nomenclature for steatotic liver disease, puts the therapeutic advance of resmetirom into context, and looks to the future for MASLD and MASH.
